Panagiotis Koufargyris

Panagiotis Koufargyris

Auto-generated profile, based on publicly available information

Panagiotis Koufargyris

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EKEvdoxia Kyriazopoulou
Evdoxia Kyriazopoulou
GPGaryfallia Poulakou
Garyfallia Poulakou
HMHaralampos Milionis
Haralampos Milionis
SMSimeon Metallidis
Simeon Metallidis
GAGeorgios Adamis
Georgios Adamis
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml−1, 85.9% (n = 510) of whom were receiving dexamethasone. At day 28, the adjusted proportional odds of having a worse clinical status (assessed by the 11-point World Health Organization Clinical Progression Scale (WHO-CPS)) with anakinra, as compared to placebo, was 0.36 (95% confidence interval 0.26–0.50). The median WHO-CPS decrease on day 28 from baseline in the placebo and anakinra groups was 3 and 4 points, respectively (odds ratio (OR) = 0.40, P < 0.0001); the respective median decrease of Sequential Organ Failure Assessment (SOFA) score on day 7 from baseline was 0 and 1 points (OR = 0.63, P = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45, P = 0.045), and hospital stay was shorter.

1 October 2020 in Cell
Verified
Journal Article
Closed access
EGEvangelos J. Giamarellos-Bourboulis
Evangelos J. Giamarellos-Bourboulis
MTMaria Tsilika
Maria Tsilika
SMSimone Moorlag
Simone Moorlag
NANikolaos Antonakos
Nikolaos Antonakos
AKAntigone Kotsaki
Antigone Kotsaki
MNMihai G. Netea
Mihai G. Netea

23 October 2024 in EBioMedicine
Verified
Journal Article
Open access
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
MAMassimo Antonelli
Massimo Antonelli
FBFrank Bloos
Frank Bloos
IKIoanna Kotsamidi
Ioanna Kotsamidi
CPChristos Psarrakis
Christos Psarrakis
Michael BauerMichael Bauer
Michael Bauer
Endotype classification becomes the cornerstone of understanding sepsis pathogenesis. Macrophage activation-like syndrome (MALS) and immunoparalysis are the best recognized major endotypes, so far. Interferon-gamma (IFNγ) action on tissue macrophages stimulates the release of the cytotoxic chemokine CXCL9. It was investigated if this mechanism may be an independent sepsis endotype. In this cohort study, 14 patient cohorts from Greece, Germany and Italy were studied. The cohorts were 2:1 randomly split into discovery and validation sets. Sepsis was defined by the Sepsis-3 definitions and blood was sampled the first 24 h from meeting the Sepsis-3 definitions. Concentrations of IFNγ, CXCL9, IP-10 (IFNγ induced protein-10), soluble CD163 and ferritin were measured. The endotype of IFNγ-driven sepsis (IDS) was defined in the discovery set as the combination of a) blood IFNγ above a specified cut-off associated with the minimal risk for immunoparalysis (defined as ≥8000 HLA-DR receptors on CD45/CD14-monoytes); and b) increase of CXCL9. Results were compared to the validation set. 5503 patients were studied; 3670 in the discovery set and 1833 in the validation set. IDS was defined as IFNγ more than 3 pg/ml and CXCL9 more than 2200 pg/ml. The frequency of IDS in the discovery set was 19.9% (732 patients; 95% confidence intervals-CIs 18.7–21.3%) and in the validation set 20.0% (366 patients; 95% CIs 18.2–21.9%). Soluble CD163, a marker of macrophage activation, was greater in IDS and IDS had features distinct from MALS. The mortality in IDS patients was 43.0% (315 patients; 95% CIs 39.5–46.6%) in the discovery set and 40.4% in the validation set (148 patients; 95% CIs 35.5–45.5%) (p = 0.44 compared to patients of the discovery set). IDS was an independent risk factor for death in the presence of other endotypes, severity scores and organ dysfunctions of the multivariate model [hazard ratio 1.71 (95% CIs 1.45–2.01) in the discovery set and 1.70 (95% CIs 1.34–2.16) in the validation set]. Decreases of IFNγ and CXCL9 blood levels within the first 72 h were associated with better outcome. IDS is a new sepsis endotype independently associated with unfavorable outcome. 10.13039/501100023710 Hellenic Institute for the Study of Sepsis ; 10.13039/100010661 Horizon 2020 project ImmunoSep; Swedish Orphan BioVitrum AB (publ) and 10.13039/501100002347 German Federal Ministry of Education and Research .

8 October 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EKEvdoxia Kyriazopoulou
Evdoxia Kyriazopoulou
GPGaryfallia Poulakou
Garyfallia Poulakou
HMHaralampos Milionis
Haralampos Milionis
SMSimeon Metallidis
Simeon Metallidis
GAGeorgios Adamis
Georgios Adamis
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis

26 March 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
GRGeorgios Renieris
Georgios Renieris
DDDionysia-Eirini Droggiti
Dionysia-Eirini Droggiti
KKKonstantina Katrini
Konstantina Katrini
PKPanagiotis Koufargyris
Panagiotis Koufargyris
TGTheologia Gkavogianni
Theologia Gkavogianni
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
Hydrogen sulfide (H2S) has recently been recognized as a novel gaseous transmitter with several anti-inflammatory properties. The role of host- derived H2S in infections by Pseudomonas aeruginosa was investigated in clinical and mouse models. H2S concentrations and survival was assessed in septic patients with lung infection. Animal experiments using a model of severe systemic multidrug-resistant P. aeruginosa infection were performed using mice with a constitutive knock-out of cystathionine-γ lyase (Cse) gene (Cse-/-) and wild-type mice with a physiological expression (Cse+/+). Experiments were repeated in mice after a) treatment with cyclophosphamide; b) bone marrow transplantation (BMT) from a Cse+/+ donor; c) treatment with H2S synthesis inhibitor aminooxyacetic acid (ΑΟΑΑ) or propargylglycine (PAG) and d) H2S donor sodium thiosulfate (STS) or GYY3147. Bacterial loads and myeloperoxidase activity were measured in tissue samples. The expression of quorum sensing genes (QS) was determined in vivo and in vitro. Cytokine concentration was measured in serum and incubated splenocytes. Patients survivors at day 28 had significantly higher serum H2S compared to non-survivors. A cut- off point of 5.3 μΜ discriminated survivors with sensitivity 92.3%. Mortality after 28 days was 30.9% and 93.7% in patients with H2S higher and less than 5.3 μΜ (p = 7 x 10−6). In mice expression of Cse and application of STS afforded protection against infection with multidrug-resistant P. aeruginosa. Cyclophosphamide pretreatment eliminated the survival benefit of Cse+/+ mice, whereas BMT increased the survival of Cse-/- mice. Cse-/- mice had increased pathogen loads compared to Cse+/+ mice. Phagocytic activity of leukocytes from Cse-/- mice was reduced but was restored after H2S supplementation. An H2S dependent down- regulation of quorum sensing genes of P.aeruginosa could be demonstrated in vivo and in vitro. Endogenous H2S is a potential independent parameter correlating with the outcome of P. aeruginosa. H2S provides resistance to infection by MDR bacterial pathogens.

29 December 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
GTGeorgios Tavoulareas
Georgios Tavoulareas
OKOlga Kontakou-Zoniou
Olga Kontakou-Zoniou
NANikolaos Antonakos
Nikolaos Antonakos
ETElisavet Tasouli
Elisavet Tasouli
GAGeorge Adamis
George Adamis
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
Early recognition of risk of death in pneumonia and start of precision immunotherapy to improve outcomes is an unmet need. We hypothesized that a precision strategy approach combining early recognition of interleukin (IL)-1 activation coupled with Anakinra treatment may improve pneumonia outcome. INSPIRE is a prospective, double-blind randomized placebo-controlled trial which recruited hospitalized adults with community-acquired or hospital-acquired pneumonia, with qSOFA (quick sequential organ failure assessment) equal to 1 and plasma presepsin (soluble CD14) more than 350 pg/ml. Patients were 1:1 randomised to standard-of-care medication plus either subcutaneous placebo or subcutaneous Anakinra 100 mg once daily for 10 days. The primary endpoint was progression into organ dysfunction defined as meeting at least one of the following two conditions; (i) at least 2-point increase of the baseline SOFA score by day 7 and/or (ii) death by day 90. This was analyzed in the intention-to-treat (ITT) population. This trial is registered with the EU Clinical Trials Register (2022-002390-28) and ClinicalTrials.gov (NCT05785442). Patients were enrolled between March 2023 and June 2024; 30 patients in the placebo arm and 30 patients in the Anakinra arm were the ITT population. The primary endpoint was met in 50·0% (15 patients) of placebo-treated and in 20·0% (6 patients) of Anakinra-treated patients (difference 30·0% [5·9 to 49%]; p: 0·011). 90-day mortality was 43·3% (13 patients) and 20·0% (6 patients) (difference 23·3% [0 to 43·7%]; p: 0·029). The overall incidence of serious treatment-emergent adverse events (TEAEs) in the placebo group was 50% and in the Anakinra group 33·3%. None of the serious TEAEs was judged to be related to treatment assignment. Production of TNFα and ΙFNγ by blood mononuclear cells was decreased. Presepsin-guided Anakinra treatment prevents progression of pneumonia to organ dysfunction and death. The mechanism of benefit is associated with attenuation of cytokine production. 10.13039/501100023710 Hellenic Institute for the Study of Sepsis ; PHC Europe BV; 10.13039/501100012112 Swedish Orphan Biovitrum AB .